 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > CollaGenex Pharmaceuticals, Inc.
 |
CollaGenex Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
CollaGenex develops drugs for dental diseases. The company's flagship product, Periostat, inhibits the tissue damage resulting from periodontal infections. It licensed the drug's underlying technology from the State University of New York. CollaGenex is exploring other possible applications of the technology, including cancer, osteoporosis, and arthritis treatment; drug candidate Metastat may fight Kaposi's sarcoma. CollaGenex also markets Merck's painkiller Vioxx to dentists. Customers include McKesson HBOC (more than 30% of sales), Cardinal Health, Bergen Brunswig, and Walgreens. Director Stephen Kaplan, through investment firm Oaktree Capital Management, owns almost 20% of the company.
COMPETITION |
 |
AstraZeneca PLC (AZN)
Atrix Laboratories, Inc. (ATRX)
OraPharma, Inc. (OPHM)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 24.30
1-Yr. Sales Growth: 50.9%
Employees: 146
Revenue per employee: $166,438.36
KEY PEOPLE |
 |
Brian M. Gallagher
CEO
Nancy C. Broadbent
CFO
CONTACT INFO |
 |
41 University Dr., Ste. 200
Newtown, PA 18940
US
Phone: 215-579-7388
Fax: 215-579-8577
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |